Global LMR Communications Provider Hytera Sues Motorola Solutions Under Sherman Antitrust Act Alleging Anticompetitive Practices That Force US Customers to Pay a Surcharge for Safety
Hytera Communications Corporation Ltd. today filed suit in federal district court in New Jersey against Chicago, Ill.-based Motorola Solutions, Inc., alleging that Motorola Solutions is engaging in anticompetitive practices that are unlawful under the Sherman and Clayton Acts by deliberately and actively foreclosing competition in land mobile radio (LMR) communications systems, in order to reap billions of dollars on sales at inflated prices to US customers.
Hytera's complaint alleges that Motorola Solutions prevents Hytera from competing in the US marketplace with its critical communications products that offer best-in-class features and far better value to public safety organizations, municipal governments, businesses, and taxpayers. Hytera further alleges that Motorola Solutions maintains its monopoly and enforces its inflated prices in the US by engaging in a monopolistic scheme that includes forcing LMR dealers to drop Hytera's products, leveraging its dominance of the US public safety market to impede adoption of newer, less expensive technologies here in the US, and engaging in a serial pattern of sham litigation to impede Hytera and interfere with its relationships with dealers and customers.
"Motorola Solutions is forcing US customers to pay artificially high prices for critical communications. It can do this because of its long-standing monopoly," notes Tom Wineland, Director of Sales for Hytera Communications America (West), Inc. "Motorola Solutions is doing this as security risks in the US are increasing, with a growing need for mission-critical communications solutions that help organizations to protect important utilities, provide safety and services for public transportation systems, and respond to threats at events such as concerts, festivals, and sports events, even in our nation's schools. All these demands put pressure on organizational budgets, and in turn are costing taxpayers and the American public."
Shenzhen-based Hytera, Jersey City, N.J.-based PowerTrunk, Inc., Miramar, Fla.-based Hytera America, Inc., Irvine, Calif.-based Hytera Communications America (West), Inc., and Cambridge, UK-based Sepura PLC together allege that by foreclosing competition from Hytera’s DMR and TETRA solutions, Motorola Solutions is able to maintain inflated pricing in the US on its P25-compliant products. P25 is a technology standard for public safety LMR in the US. TETRA, used by public safety organizations and commercial businesses worldwide, offers similar functionality and features to P25 equipment and can be significantly less expensive, making it a compelling option for utilities and transportation organizations and other commercial users in the US. Hytera’s complaint provides the example of two competing professional DMR handsets with similar features and functionality: Motorola Solutions’ suggested retail price (MSRP) is as much as $738, nearly twice Hytera’s MSRP of $440.
Hytera further alleges that Motorola Solutions is charging US customers more than it charges customers in competitive markets outside the US. Hytera gives an example that, even after Motorola applied discounts to its list price, it charged the City of Chandler, Ariz., $5,290 for a P25-compliant radio -- nearly five times what a customer in the UK could pay at retail for a comparable TETRA product. Hytera explains that US customers and American taxpayers could realize significant savings from competition from more cost-effective TETRA and DMR solutions that are just as robust.
"The only thing this pricing adds up to is more profit for Motorola Solutions -- with taxpayers on the hook," Wineland says. "Customers want a choice, as reflected by the demand by public safety customers and other US customers for DMR, a robust LMR alternative at a fraction of the cost of P25."
Hytera points out that Motorola Solutions has built a moat around the US public safety market, making continuous efforts to stall acceptance in the US of TETRA-compliant LMR. Hytera also notes that Motorola Solutions has engaged in a pattern of intimidation of LMR dealers. "Motorola Solutions brow-beats dealers into dropping Hytera's products or face losing the ability to sell Motorola Solutions' products and service lucrative maintenance contracts," notes Andrew Yuan, Hytera's President of North and South America, based in Irvine, Calif.
"Hytera provides feature-rich, high-quality solutions at a competitive price. Motorola Solutions is a monopolist charging US businesses a surcharge for safety, and those costs are passed on to taxpayers and the general public," adds Mark Jordan, Regional Sales Manager for Hytera Communications America (West). "Motorola Solutions is badgering dealers to drop Hytera, preventing adoption of standards that would lower prices for customers, and using courts to damage Hytera's relationships with LMR dealers and customers and raise our cost of doing business."
Hytera details how Motorola Solutions has engaged in a pattern of sham litigation and regulatory actions to raise costs for Hytera and sow anxiety in the market, diminishing competition. This includes suing Hytera for patent infringement on a set of standard essential technologies that industry users have agreed to license on fair, reasonable, and non-discriminatory (FRAND) terms, and for which Hytera has already been paying Motorola Solutions to license.
"Customers in the US deserve the best critical communications equipment and technology at the best prices," adds Wineland. "Customers love Hytera's products—and the value they receive. American customers are paying far more to Motorola Solutions and getting less, and Motorola Solutions is working hard to maintain that unfair pricing regime here."
Hytera Communications Corp., Ltd., et al. v. Motorola Solutions, Inc., 2:17-cv-12445 (D.N.J.) alleges that Motorola Solutions has violated federal and state antitrust law by violating Sections 1 and 2 of the Sherman Antitrust Act and Section 3 of the Clayton Act, and the unfair competition and intentional interference laws of the states of New Jersey, California and Florida. Hytera is seeking damages and injunctive relief.
Hytera is represented by Noah Brumfield, Jason Zakia, Yi Ying, and Jeremy K. Ostrander of White & Case LLP and by Liza M. Walsh, Tricia B. O’Reilly, Marc D. Haefner, Katherine Romano, and Katelyn O’Reilly of Walsh Pizzi O'Reilly Falanga LLP.
Hytera Communications Corporation Limited is a leading global provider of innovative professional land mobile radio (LMR) communications solutions to governmental organizations, public security institutions, and customers from other industries including transportation, oil and gas, and many others around the world. Founded in Shenzhen, China in 1993 and listed on the Shenzhen Stock Exchange (002583.SZ), Hytera has ten research and development centers around the world and has partnered with companies in the U.S. since 2000. Hytera established its first U.S. subsidiary, Hytera America, Inc., in 2004. It established Hytera Communications America (West), Inc., in 2016. Hytera owns PowerTrunk, Inc., and Sepura LLC, and has research and servicing facilities in Schaumburg, Ill. More information is at www.hytera.com.
Hytera Communications America (West), Inc.
Kevin Nolan, +1 469-206-8170
Director of Marketing
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma21.10.2018 10:45 | Pressemelding
Incyte Corporation (Nasdaq:INCY) announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment. In patients with FGFR2 translocations who were followed for at least eight months, interim study results demonstrated an overall response rate (ORR) of 40 percent, the primary endpoint, and a median progression free survival (PFS) of 9.2 months, a key secondary endpoint. These results are being presented at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany in a poster presentation on Sunday, October 21 from 12:45 p.m. CEST to 1:45 p.m. CEST (6:45 a.m. ET to 7:45 a.m. ET). (Location: Hall A3 – Poster Area Networking Hub; Abstract #756P) “We are pleased to share updated interim results from our ongoing FIGHT-202 trial
Servier and Taiho Oncology Announce Phase III LONSURF® Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer21.10.2018 09:10 | Pressemelding
Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today clinical data from the pivotal Phase III TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pre-treated metastatic gastric cancer who have progressed or are intolerant to previous lines of therapy. The study met its primary endpoint of prolonged overall survival (OS) and secondary endpoint measures of progression-free survival (PFS) consistently supported the OS results, as well as continuing to demonstrate the predictable safety and tolerability profile of trifluridine/tipiracil. Data from TAGS was presented by Dr. Hendrik-Tobias Arkenau, Executive Medical Director of the Sarah Cannon Research Institute UK and an investigator for TAGS, at the ESMO 2018 Congress in Munich, Germany during an oral session (Abstract #LBA25). The study results were simultaneously published in
Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting20.10.2018 22:30 | Pressemelding
Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent
Manchester United and True Religion Launch Denim Range19.10.2018 17:37 | Pressemelding
Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion
Arch Insurance Announces Strategic Leadership Changes19.10.2018 13:10 | Pressemelding
Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These
Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 12:00 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an